^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRCA mutation

    i
    Other names: BRCA, Breast cancer, early onset
    Related biomarkers:
    Expression
    CNA
    Others
    9ms
    ⁦@US_FDA⁩ ‘s Withdrawal of Later-Line Indication For #Olaparib in #BRCA Mutated #OvarianCancer ⁦@OncLive⁩ #gyncsm #womenshealth #cancerresearch #PARP https://t.co/MY9RghtCLp (@LguzzardiM)
    BRCA (Breast cancer early onset) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
    |
    BRCA mutation
    |
    Lynparza (olaparib)
    9ms
    Honored to be on the @FacingOurRisk blog! Our intense song “Mutant” is about my #BRCA mutation and was recorded by mother & daughter together: https://t.co/7OpFSjDJLU @geneticcouns @karenlumd #ovariancancer @GildasClubNYC @joliestweet @mathewknowles @1capplegate @themorganwade (@the_mothermold)
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    10ms
    Yeah. My patient with family hypercolesterolemia ... I really have been dismissing the psychology behind it... And women with BRCA mutations and extremely early onset breast cancer, if only they had done some therapy... YOU ARE A FRAUD. (@RPLerias)
    Clinical
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    10ms
    Honestly this is where I see this being used Pt gets ADT+Abi in mCSPC & than progresses and has BRCA mutation (@BijoyTelivala)
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    10ms
    Esp with approval for prostate cancer harboring "HRR mutations", rather than only specific types like BRCA. The subgroup data presented at ASCO is helpful to guide realistic expectations based on the specific HRR mutation for a patient. 👏💡 (@MehtaScribe)
    Clinical
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    11ms
    For patients with cancer, assessment for the potential of familial (germline) pathogenic mutations (like #BRCA) is recommended, but infrequently performed. When done, it's very informative https://t.co/enx6QiJ97I @JAMA_current (@EricTopol)
    Clinical
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    11ms
    Agree this was a great presentation representing a phenomenal amount of work from @Dolmos77 @Ecastromarcos and team - powerful validation of the negative prognostic impact of BRCA gene mutations in mCRPC. Looking forward to the paper! #ASCO2023 (@ResearchWyatt)
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    11ms
    #ASCO23 en su día 3 me hizo maravillarme con talazoparib. Les cuento que en mayo por 1a vez atendí a una paciente con cáncer de mama TNBC avanzada bajo 1L con talazoparib por ser BRCA mutada. Estaba empezando a responder como si lo hiciera con platinos, pero con mejor tolerancia! (@EoHeb)
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Talzenna (talazoparib)
    11ms
    @Dolmos77 presenting excellent data in how #BRCA mutations predict worse outcomes in patients with prostate cancer. A 10 month OS difference in mCRPC. We need to screen all patients with metastatic and high risk disease! -@BGarmezy @SarahCannonDocs #ASCO2023 #pcsm (@OncLive)
    Clinical • Metastases
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    11ms
    Results show that durvalumab plus olaparib added to standard care improves PFS in newly diagnosed advanced #ovariancancer w/out BRCA mutation. Findings were introduced in an #ASCO23 news briefing. @DrMarkham of @UFMedicine shares insights. #onctwitter https://t.co/sfEx1ErEbz (@OBRtweets)
    Metastases
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab)
    11ms
    On May 31, the @US_FDA approved olaparib plus abiraterone and prednisone or prednisolone in adult patients with mCRPC with BRCA mutations based on findings from the PROpel trial (NCT03732820). Dr. @AarmstrongDuke @DukeGUCancer weighs in. (@DukeCancer)
    Clinical • FDA event
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • abiraterone acetate • prednisone
    11ms
    WATCH: @AarmstrongDuke, of @DukeCancer, discusses the significance of the FDA approval of olaparib plus abiraterone acetate and prednisone or prednisolone in patients with BRCA-mutated metastatic castration-resistant prostate cancer. #pcsm https://t.co/DpJtToQdQ0 (@OncLive)
    Clinical • FDA event • Metastases
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • abiraterone acetate • prednisone
    11ms
    LYNPARZA® (olaparib) + abiraterone approved in the US for the treatment of BRCA-mutated #mCRPC. Approval based on a subgroup analysis of the PIII #PROpel trial #ReadNow details on UroToday > https://t.co/dZpX6CTT9E @AstraZeneca @Merck @AarmstrongDuke @LYNPARZAhcp @FoundationATCG (@urotoday)
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • abiraterone acetate
    11ms
    WATCH: Dr Armstrong on the FDA Approval of Abiraterone/Olaparib Combination in BRCA-mutated mCRPC @AarmstrongDuke @DukeCancer @US_FDA #pcsm https://t.co/m0KuRlI4JO (@OncLive)
    FDA event
    |
    BRCA (Breast cancer early onset) • RMST (Rhabdomyosarcoma 2 Associated Transcript)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • abiraterone acetate
    11ms
    @DFCI_BreastOnc is leading a phase II study of niraparib with dostarlimab therapy as neoadjuvant treatment for patients with BRCA-mutated #BreastCancer. For more information call 877-338-7425 or visit: https://t.co/i1n8wfgEA3 @elmayermd (@DFCI_BreastOnc)
    Clinical
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    11ms
    When you find a #BRCA mutation on cancer tissue or ctDNA, always remember to evaluate the germline mutation status! In #breastcancer: gBRCA 👉 ESCAT IA sBRCA 👉 ESCAT IIIA #ESMOBreast23 @myESMO (@angela_toss)
    Circulating tumor DNA
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    12ms
    @ancan501c3 is lobbying @FoundationATCG to remove actionability in #prostatecancer for non-#BRCA HRR mutations. Getting pushback! Maybe Friday's FDA meeting will help. @EfstathiouEleni @charlesryanmd @Daniel_J_George @EAntonarakis @PCFnews @ZEROCancer (@ancan501c3)
    FDA event
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    12ms
    🆕ODAC supported FDA approval of Olaparib + abiraterone (abi/pred) for 1L of patients with BRCA-mutated mCRPC based of the results of the PROPEL trial. https://t.co/q6CBMBgQRu. (@fedelosco)
    Clinical • FDA event • ODAC
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • abiraterone acetate
    12ms
    📢Zapraszamy wspólnie z @rutkowskip1972, @OnkologiaPolska i @NIO_PIB na #konferencje✴️#Onkologia precyzyjna w praktyce klinicznej, gdzie omówione zostaną m. in. #immunoterapia precyzyjna, leczenie ukierunkowane molekularnie, program #NTRK i mutacje #BRCA.➡️https://t.co/KYLyI1GnSY (@ViaMedica_pl)
    BRCA (Breast cancer early onset) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRCA mutation
    1year
    Men & BRCA Program Director Kara Maxwell, MD, PhD discusses advancements in #prostatecancer at #AACR2023. Our Men & BRCA program was built to propel research and education focusing on men with BRCA mutations. @PennMDForum @AACR @KMaxwellLab Learn more: https://t.co/otZTexAmSM (@BasserBRCA)
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    1year
    DUO-O, pase III trial evaluating durvalumab in combination with chemotherapy and bevacizumab, followed by maintenance durva, bev and olaparib improved PFS in patients with advanced ovarian cancer without tumor BRCA mutations. @BHCancerCare #ovariancancer #Immunotherapy (@johndiazmd)
    Clinical • Combination therapy • IO biomarker • Metastases
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab)
    1year
    #TumorBoardTuesday There have been some exciting updates this weekend at #AACR23 on DDR and Breast Cancer‼️ So the discussion🗣️by @JenniferLitton & @marijasullivan tomorrow, 04/18/2023 at 8PM on treating early stage BRCA-mutated Breast Cancer is very timely⏲️ (@TumorBoardTues)
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    1year
    Just a small part of the team behind the 10020 trial comparing #olaparib to a combination of olaprib with #atezolizumab for #BRCA-mutant breast cancer! Exciting to be on this with ⁦@AACR⁩ incoming president #PatLorusso & @yale’s #KristinaFanucci! (@EladSharonMD)
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Tecentriq (atezolizumab)
    1year
    Shannon N. Westin, MD, MPH, on Ovarian Cancer: Results From the NOW Trial of Neoadjuvant Olaparib in BRCA-, PALB-, or RAD51C–Mutant Disease https://t.co/DCyeYBy47J #gyncsm #ovariancancer #genetics #oncology #SGO23 #SGO_mtg @SGO_org @ShannonWestin @MDAndersonNews (@ASCOPost)
    Clinical
    |
    BRCA (Breast cancer early onset) • RAD51C (RAD51 paralog C)
    |
    BRCA mutation • RAD51 mutation
    |
    Lynparza (olaparib)
    1year
    Excellent overview by @UFHealthCancer gynecologic oncologist Dr. Burak Zeybek of where things stand in the study of neoadjuvant PARPi in newly diagnosed BRCA mutated #ovariancancer. @DrMarkham #gyncsm https://t.co/gUGcSNs4SI (@DrMMurphy)
    Clinical
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    1year
    *From #TumorBoardTuesday archives* 📖As we prepare for our next #BreastCancer case, take a look at @jane_meisel @quirogad case presentation from December 2022 on 2L for BRCA mutation & wrap up. @MPishvaian @JohnEbbenMDPhD @JenniferLitton @marijasullivan https://t.co/Ocv4DXS1rr (@TumorBoardTues)
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    1year
    Quintuple Regimen Prolongs PFS in Advanced, High-Grade Epithelial Ovarian Cancer +/- BRCA Mutations https://t.co/org12ENjBk vía @targetedonc. Good news for our patients! Cant wait to see the value of Durvalumab to the combination! @GEICOgroup (@AviRamchandani)
    Clinical • Metastases
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Imfinzi (durvalumab)
    1year
    Good news for breast cancer patients with the BRCA gene mutation: NHS in England agrees to fund their treatment with PARP inhibitor. 👇🏻 https://t.co/tJhAL5crin (@RobClarkeLab)
    Clinical
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    1year
    Neoadjuvant treatment w/ olaparib prior to surgical resection & adjuvant chemotherapy was well tolerated & led to a 100% optimal resection rate in newly diagnosed, BRCA-mutant ovarian, primary peritoneal, or fallopian tube cancer. @ShannonWestin #gyncsm https://t.co/OUuquGHRXl (@OncLive)
    Clinical
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib)
    1year
    @DFCI_BreastOnc is leading a phase II study of niraparib with dostarlimab therapy as neoadjuvant treatment for patients with BRCA-mutated #BreastCancer. For more information call 877-338-7425 or visit: https://t.co/i1n8wfgEA3 @elmayermd (@DFCI_BreastOnc)
    Clinical
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    1year
    Opening up a new interesting window of opportunities for PARPi in ovarian cancer! @OncLive @IJGConline @IJGCfellows @ShannonWestin @MDAndersonNews Neoadjuvant Olaparib Proves Feasible, Aids Optimal Resection in BRCA-Mutant Ovarian Cancer https://t.co/uhr1eWwjxi via @onclive (@gcarusomd)
    Clinical
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib)
    1year
    Neoadjuvant Olaparib WINDOW Trial in Newly diagnosed BRCA mutant high grade serous ovarian cancer (including RAD51C, PALB2): 53% PR, 46% SD, 0% PD, 1 patient with pathological CR, 85% no gross residual dz, 14% < 1cm residual. #SGO_org, #SGOmtg, #SGO23, #PatientsPurposeProgress (@ChristiKimMD)
    Clinical
    |
    PALB2 (Partner and localizer of BRCA2) • BRCA (Breast cancer early onset) • RAD51C (RAD51 paralog C)
    |
    PALB2 mutation • BRCA mutation • RAD51 mutation
    |
    Lynparza (olaparib)
    1year
    Amazing work by my friend and co-fellow @HanTCun who presented her work on identifying an exosomal-derived biomarker signature for early detection of ovarian cancer in brca mutation carriers. @MDAndersonNews @aaronshafer99 @karenluMD #sgo2023 #sgomtg (@jahow514)
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    1year
    Fascinating work presented by @ShannonWestin & MD Anderson team at #SGOmtg - pilot ovarian cancer study of pre-surgery PARP inhibitor in those w/ BRCA & other mutations. 54% partial response rate, no progression of disease, no suboptimal resection at surgery. (@bjdmatthews)
    Clinical • Surgery • Pre-surgery
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    1year
    @ShannonWestin neoadjuvant PARPi #olaparib feasible in patients with BRCA mutated ovarian cancer! @SGO_org Same concept under investigation in Seattle at Swedish. #opalcohortc #clinicaltrials (@fmusaMD)
    Clinical
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib)
    1year
    @MDAndersonNews ‘s Dr @ShannonWestin presenting the NOW (neoadj olaparib window) trial in newly dx #BRCA mutant ovarian ca: excellent cytoreductive surgical outcomes seen with only 2C of neoadj olaparib (@JulieSammouri)
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib)
    1year
    @ShannonWestin presenting NOW (neoadj ov window). Neoadjuvant #olaparib in BRCA mutated ovarian cancer pts. Interesting early results with fewer adj chemo cycles and CGR at surgery. Stay tuned... #SGOmtg #sgo2023 (@drjoeng)
    Clinical • Surgery
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib)
    1year
    The future of neoadjuvant chemotherapy in #BRCA mutated #ovariancancer @ShannonWestin @MDAndersonNews #SGOMtg #sgo2023 #oncsurgery #gyncsm (@nicoleflemingmd)
    Clinical • Surgery
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    1year
    Congrats ⁦@ShannonWestin⁩ neoadjuvant PARPi #olaparib feasible in patients with BRCA mutated ovarian cancer! ⁦@SGO_org⁩ ⁦@GOG⁩ ⁦@acog⁩ ⁦@gyncsm⁩ ⁦@SHAREing⁩ (@BPothuri)
    Clinical
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib)
    1year
    .@ShannonWestin @MDAndersonNews presenting neoadjuvant Olaparib study in #BRCA mutated #ovariancancer @SGO_org #SGOMtg #sgo2023 #oncsurgery #gyncsm (@nicoleflemingmd)
    Clinical • Surgery
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib)
    1year
    Obesity May Exacerbate Breast Cancer Risk in Women with BRCA Mutations | Newsroom | Weill Cornell Medicine https://t.co/joFOQQFut0 (@NeilFlochMD)
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    1year
    Still time to register for @YodeahKnow upcoming webinar about prevention of genetic mutations such as #Brca #hereditarycancer in future generations! @MyJScreen @CarmenCalfa @DenseBreastInfo @DrSueGross @BasserBRCA @inheritedcancer @FacingOurRisk @PowerOvarian @LguzzardiM (@EtkinKramer)
    BRCA (Breast cancer early onset)
    |
    BRCA mutation